TissueCypher optimized adherence to clinical guidelines for surveillance and treatment of both BE patients at high and low risk for disease progression. Use of the test can enable physicians to make risk-aligned management decisions, leading to improved patient health outcomes.

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis.

Utilizing the 40-GEP test results to guide ART decision-making would result in material savings to Medicare.

In a head-to-head comparison of DecisionDx-Melanoma to AJCCv8 staging for stage I cutaneous melanoma (CM) patients (n=6,883) two cohorts were analyzed using recurrence-free survival and melanoma-specific survival. Results from the study showed that DecisionDx-Melanoma significantly improved patient risk stratification, independent of AJCC staging in patients. In addition, DecisionDx-Melanoma provided greater separation between high-risk (Class 2B) and low-risk (Class 1A) groups than seen between AJCC stage IA and IB.

A case report describing how MyPath GEP testing leads to diagnostic clarity in a histopathologically ambiguous melanocytic lesion on the face of a 34-year-old man.

A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.

Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions

Management guided by the TSP-9 test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.